876 / 1224
/
ESTRO SBRT Course 2015 - Emerging SBRT indications
7
• RCHT well tolerated
• No improvement of OS, median 15 – 16.5 mo
• Boarderline improvement of PFS
Pancreatic cancer – PAP 007
Hammel YAMA 2016
Overall survival
PF survival